References
- Task Force on Myocardial Revascularization of the European Society of C, the European Association for Cardio-Thoracic S, European Association for Percutaneous Cardiovascular I, et al. Guidelines on myocardial revascularization. Eur Heart J. 2010;31(20):2501–2555.
- FDA. Pre market approval: Edwards Sapien transcatheter heart valve and accessories. 2012. Accessed December 5, 2020. https://wwwaccessdatafdagov/scripts/cdrh/cfdocs/cfpma/pmacfm?id=P110021.
- Services. CfM. National Coverage Determination (NCD) for Transcatheter Aortic Valve Replacement (TAVR) (20.32). 2019. Accessed December 5, 2020. https://wwwcmsgov/medicare-coverage-database/details/ncd-detailsaspx?NCDId=355.
- Holmes DR Jr., Mack MJ, Kaul S, et al. 2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement. J Am Coll Cardiol. 2012;59(13):1200–1254. doi:10.1016/j.jacc.2012.01.001.
- O’Riordan M. Former EXCEL investigator alleges trial manipulation, prompting vehement denials. tctmdcom. Accessed December 5, 2020. 2019. https://www.tctmd.com/news/former-excel-investigator-alleges-trial-manipulation-prompting-vehement-denials.
- Coylewright M, Forrest JK, McCabe JM, Nazif TM. TAVR in low-risk patients: FDA approval, the new NCD, and shared decision-making. J Am Coll Cardiol. 2020;75(10):1208–1211. doi:10.1016/j.jacc.2019.12.057.
- Maxwell Y. 2016 heart team survey. 2016. Accessed December 5, 2020. https://s3amazonawscom/prodtctmdcom/public/2020-01/TCTMD16-Heart-Team-Survey-Infographics-08-Portraitpdf.